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Bacteriocins are proteinaceous antibacterial compounds, produced by diverse bacteria,
which have been successfully used as: (i) food biopreservative; (ii) anti-biofilm agents;
and (iii) additives or alternatives to the currently existing antibiotics, to minimize the risk
of emergence of resistant strains. However, there are several limitations that challenge
the use of bacteriocins as biopreservatives/antibacterial agents. One of the most
promising avenues to overcome these limitations is the use of nanoformulations. This
review highlights the practical difficulties with using bacteriocins to control pathogenic
microorganisms, and provides an overview on the role of nanotechnology in improving
the antimicrobial activity and the physicochemical properties of these peptides.
Keywords: bacteriocin, antimicrobial peptides, biopreservative, nanotechnology, nanoformulated bacteriocins,
drug delivery systems
INTRODUCTION
Bacteriocins are a group of polypeptides that are produced by a variety of Gram-negative and
Gram-positive bacteria, and exhibit bactericidal or bacteriostatic activity, usually against species
closely related to the producing strain (Tagg et al., 1976; Castellano et al., 2012; El-Gendy et al.,
2013). While they may be categorized as antibiotics, bacteriocins differ in that they are: (i)
proteinaceous, ribosomally synthesized, molecules produced during the primary phase of growth;
(ii) known to exhibit a relatively narrow spectrum of antibacterial activity; (iii) inactivated by
digestive enzymes, which makes them non-toxic to human cells if used as biopreservative; and
(iv) unique in their mechanism of action (Tagg et al., 1976; Zacharof and Lovitt, 2012; Balciunas
et al., 2013; Perez et al., 2014). Regarding the structure, classification, mode of action, and
genetic characterization of bacteriocins, these aspects have been discussed in a number of reviews
(Klaenhammer, 1993; Héchard and Sahl, 2002; Nes et al., 2007; Hoover and Steenson, 2014) and
will not be covered here.
Over the last decade, bacteriocins have gained considerable attention due to their potential
applications in the food industry as natural biopreservatives, and more recently in the health
industry as antimicrobial agents (Zacharof and Lovitt, 2012; El-Gendy et al., 2013). Regarding the
first field of application, bacteriocins can be either added directly as purified (or partially purified)
agents to food or produced through cultivation of the bacteriocin-producer strain in the food
substrate (Deegan et al., 2006). Among the advantages gained by this approach are: chemical-
free preservation, shelf-life extension, and inhibition of food-borne pathogenic bacteria during the
farming and food-processing stages (Deegan et al., 2006). Moving to the second field of application,
the expanding clinical applications of bacteriocins may help us to fill some gaps in the biomedical
sector. For example, some bacteriocins have displayed activity against Gram-positive pathogens
of human and animal origin, including methicillin-resistant Staphylococcus aureus (MRSA), and
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vancomycin-resistant Enterococcus faecalis strains (Kruszewska
et al., 2004; Millette et al., 2008). This antibacterial activity makes
bacteriocins a promising substitute or a synergistic component
to the currently used antibiotics to overcome the emergency of
bacterial resistance.
However, in spite of these promising advantages, nisin
is the only bacteriocin generally recognized as safe by the
Food and Drug Administration and is currently used as a
food preservative in several countries (Delves-Brougthon, 1990;
Montville and Chen, 1998). This limitation in bacteriocins
availability in the market as preservatives and antimicrobials
can be attributed to multiple factors, including: (i) the high
cost of their commercial production (Bradshaw, 2003); (ii)
the loss of their activity by proteolytic enzymes (Bradshaw,
2003); (iii) their unfavorable interactions with other food
constituents, which decreases the availability and necessitates
a huge amount of the peptide to be added (Jung et al., 1992;
Schillinger et al., 1996); (iv) the alterations of the chemical
and physical properties of these compounds during the various
food-processing stages (Davidson et al., 2005); (v) the low yield
of these compounds due to ineffective recovery by traditional
purification methods (Carolissen-Mackay et al., 1997); and
(vi) the narrow spectrum of activity observed for most of
the tested bacteriocins against pathogenic bacteria (Riley and
Wertz, 2002). In the last years, several studies on bacteriocins
have demonstrated that the optimization of their production
conditions, their purification methods, their combinations with
other antimicrobial agents, and the hurdle technology approach,
could all represent solutions to some of the previously mentioned
problems (Kalchayanand et al., 1994; Li et al., 2001; Wolska
et al., 2012; Saraniya and Jeevaratnam, 2014). While scientists
are searching for efficient strategies to overcome the limitations
of bacteriocins, the use of nanotechnology is a potential
approach to maximize the use of these peptides (Allémann
et al., 1998; Salmaso et al., 2004). Therefore, this article aims
to elucidate the current applications of nanotechnology in
improving the properties and the antimicrobial activity (AMA)
of bacteriocins.
ADVANTAGES OF NANOFORMULATED
BACTERIOCINS
According to the U.K. House of Lords Science and Technology
Committee, nanotechnology is the manipulation of functional
materials and structures into the nanoscale size (with diameters
ranging from 1 to <1000 nm; Klaessig et al., 2011). This
is a quite novel technology that has several applications in
various fields of science due to the unique features of the
synthesized nanoparticles (Chou et al., 2011). The integration
of nanotechnology and biotechnology opens the door to
unlimited opportunities and future perspectives to solve the
problems belonging to a range of biological products. Through
this integration, effective delivery, targeting, protection from
degradation, in addition to improving drug potency and
physicochemical properties can all be achieved (Farokhzad and
Langer, 2009). Bacteriocins are one of the many examples
that can benefit from such combination. For instance, nano-
encapsulation of bacteriocins intended for use as biopreservatives
could protect them from degradation by proteolytic enzymes,
in addition to rescuing them from undesirable interactions
with other food components, and hence, increasing their
stability for longer periods (Brandelli, 2012). Furthermore, some
recent studies have shown that encapsulation of bacteriocins in
nanoparticles has enhanced the activity of these peptides against
food-spoiling microorganisms and multidrug-resistant bacteria
(Arthur et al., 2014; Mossallam et al., 2014). In addition, the
use of nanotechnology-based materials and/or methods has, in
most cases, shown a positive impact on bacteriocin yield, thus
facilitating their commercial production (Zacharof et al., 2013).
Table 1 illustrates several examples of bacteriocins that have been
formulated using nanotechnological approaches, while Figure 1
summarizes themajor benefits form such formulations. However,
it must be stated that some of the nanoformulated bacteriocins
have nearly the same activity (or even lower) compared with the
free ones (da Silva Malheiros et al., 2012a; Malheiros Pd et al.,
2012), which will be explained below in more details.
NANOTECHNOLOGICAL APPROACHES
USED IN BACTERIOCIN FORMULATIONS
Encapsulation in Lipid-Based
Nanoparticles
Nanoliposomes
Liposomes are spherical structures composed of single or
multiple phospholipid bilayer membranes enclosing an aqueous
medium with a size ranging from nanometer to micrometer
(Bangham et al., 1965; Vemuri and Rhodes, 1995). Besides
being non-toxic, liposomes are biodegradable agents suitable
for encapsulating both hydrophilic and hydrophobic substances
(Gundermann and Schumacher, 1990; Kulkarni et al., 1995).
Especially when prepared at the nano size, nanoliposomes
represent a promising vehicle for the encapsulation and
delivery of several drugs and bioactive compounds, including
bacteriocins (Banerjee, 2001; Mugabe et al., 2005; da Silva
Malheiros et al., 2012b). For example, phosphatidylcholine-
based nanoliposomes have been shown to exhibit high
entrapment efficiency (almost 100%) for the bacteriocin-
like substance (BLS) P34, without having a negative effect on
its antimicrobial activity (da Silva Malheiros et al., 2012a).
In another study, nanoliposomes prepared from different
lipid/phospholipid compositions and ratios were tested for
their: (i) capacity to encapsulate nisin Z; (ii) stability; and
(iii) bacterial targeting (Colas et al., 2007). The highest
entrapment efficiency for nisin Z (54.2%) has been recorded for
nanoliposomes composed of dipalmitoylphosphatidylcholine/
dicetylphosphate/cholesterol (DPPC:DCP:CHOL) with 7:2:1
molar ratio (Colas et al., 2007). Additionally, nanoliposomes
prepared from DPPC:DCP:CHOL (at 7:2:1 ratio) or from
dipalmitoylphosphatidylcholine/stearylamine/cholesterol (at 7:2:
1 ratio) have been shown to possess the highest stability, which
extended for 14 months at 4◦C in case of the former, and 12
months at 25◦C in case of the latter (Colas et al., 2007). The
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FIGURE 1 | Schematic representation showing some of the nanotechnological approaches used in bacteriocin formulations with their associated
characters. 35, da Silva Malheiros et al., 2012a; 41, da Silva Malheiros et al., 2012b; 46, de Mello et al., 2013; 69, Zohri et al., 2010; 70, Zohri et al., 2013;71,
Bernela et al., 2014; 72, Chopra et al., 2014; 33, Mossallam et al., 2014; 80, Thirumurugan et al., 2013; 87, Sharma et al., 2012; 94, Heunis et al., 2013; 95, Heunis
et al., 2011; 100, Ahire and Dicks, 2015; 101, Ahire et al., 2015.
results have also shown the ability of nanoliposomes prepared
from DPPC:DCP:CHOL to target the outer membranes of
Bacillus subtilis (Colas et al., 2007). A study similar to the one
just described was conducted by Taylor et al. (2007), in which
nanoliposomes prepared from distearoylphosphatidylcholine
(PC) and distearoylphosphatidylglycerol (PG) were used to
encapsulate nisin. Their results have shown the ability of
liposomes consisting of PC, PC/PG (at 8:2), and PC/PG (at
6:4 ratio) to retain about 70–90% of the incorporated nisin
with high stability, despite exposure to elevated temperatures
(25◦–75◦C) and acidic or alkaline pH [46]. These findings
suggest that the stability of bacteriocins against unfavorable
environmental conditions can be improved by nanoliposomal
formulations, which still remains to be proved by assessing their
AMA (Taylor et al., 2007). A similar study was reported by de
Mello et al. (2013), in which pediocin AcH had been successfully
loaded with high (80%) entrapment efficiency, stability, and
antimicrobial activity, for at least 13 days, when incorporated
into phosphatidylcholine nanovesicles (de Mello et al., 2013).
However, it must be stated that while the liposome-encapsulated
pediocin has been shown to maintain its AMA for a longer
period, this activity was lower than that of the free pediocin,
which requires further investigations to overcome this issue
(de Mello et al., 2013). These collective studies indicate that
nanoliposomal formulations of bacteriocins may have distinct
capacities to withstand environmental and chemical stresses
typically encountered during the different food-processing
stages.
Protection from degradation and enhancement of stability are
not the only advantages of liposome-encapsulated bacteriocins,
as some of these formulations have exhibited better AMA, in
terms of either spectrum or duration, which will be discussed
in more details in the following paragraph. For instance,
phosphatidylcholine nanovesicles containing BLS produced from
Bacillus licheniformis P40 have been shown to completely
inhibit L. monocytogenes within the first 12min of incubation
(Teixeira et al., 2008). In terms of duration of activity, while
the encapsulated BLS has been shown to maintain its initial
AMA over 30 days of incubation, it has taken only 14 days
for the free one to lose 90% of its activity (Teixeira et al.,
2008). In terms of safety, the encapsulated BLS has been
shown to lack any hemolytic activity on human erythrocytes,
suggesting its safety as food biopreservative (Teixeira et al.,
2008). In another study, BLS P34 and nisin were encapsulated
individually in nanoliposomal formulations prepared either from
phosphatidylcholine alone or phosphatidylcholine/cholesterol
(at 7:3 ratio; da Silva Malheiros et al., 2012b). While all the
tested formulations have inhibited L. monocytogenes growth, the
phosphatidylcholine-based preparations that have been stored
for 10 days demonstrated the highest AMA against this bacterium
in Minas frescal cheese samples (da Silva Malheiros et al., 2012b).
Therefore, phosphatidylcholine nanovesicles seem to promote
the slow release of the incorporated bacteriocins, which explains
the storage duration required to exert their efficacy against target
microorganisms (da Silva Malheiros et al., 2012b).
However, in spite of the above encouraging examples,
encapsulated bacteriocins with activity similar to, or less than,
the free ones have been reported in few other studies (da Silva
Malheiros et al., 2012a; Malheiros Pd et al., 2012). For example,
when nisin has been encapsulated in phosphatidylcholine
nanoliposomes, the encapsulated and the free nisin had both
displayed nearly equal antilisterial activities (da Silva Malheiros
et al., 2010a). Additionally, while the free nisin has been shown
to maintain its AMA over 24 days of incubation, the activity
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of the encapsulated one has declined to 25% of its initial levels
after only 10 days of storage (da Silva Malheiros et al., 2010a).
Another example is the study of Malheiros Pd et al. (2012), in
which nisin encapsulated in phosphatidylcholine nanoliposomes
has only displayed a bacteriostatic effect against L. monocytogenes
in Minas frescal cheese, whereas the free nisin has exhibited a
bactericidal effect under the same conditions (da Silva Malheiros
et al., 2010a). This negative impact on bacteriocin AMA
may be attributed to: (i) selection of unsuitable phospholipid-
bacteriocin combinations; (ii) undesirable interactions between
the bacteriocin and the phospholipid forming the liposome;
(iii) stresses applied during the encapsulation process; and/or
(iv) low-purity level of the starting materials, including the
antimicrobial peptide itself (Were et al., 2003; da Silva Malheiros
et al., 2010a,b). Therefore, further studies are required to
optimize the formulation of bacteriocin-loaded liposomes, in
order to avoid the negative impacts mentioned above.
Solid Lipid Nanoparticles (SLN)
Another example of lipid-based formulation systems is SLN,
in which each nanoparticle is composed of a triglyceride core
with a phospholipid coat of high-melting point, which is
responsible for keeping them in a solid state, both at room and
human body temperatures (Puri et al., 2009). In addition to
the multiple advantages of liposomes, the solid core possessed
by SLN makes them powerful tools for large-scale production
and slow-release drug formulations (Feng and Mumper, 2013).
In a recent study, the release of nisin incorporated into SLN
carrier has continued for about 25 days, depending on the pH
and the salt concentration of the buffer solution (Prombutara
et al., 2012). Additionally, nisin-loaded SLN have demonstrated
activity against L. monocytogenes DMST 2871 for up to 20
days and activity against L. plantarum TISTR 850 for up to
15 days, while the activity of free nisin lasted only for 3 days
against the former organism and for 1 day against the latter
(Prombutara et al., 2012). This indicates that SLN have the ability
to protect bacteriocins from degradation, and hence extend their
antibacterial activity for a longer period of time. However, the
use of SLN as a delivery system for bacteriocins is still in the
early exploratory phases of research. Furthermore, there are a
number of challenges that need to be overcome to fully establish
the SLN as a delivery system; these challenges include the possible
expulsion of the incorporated drug/drug-like agents from the
lipid matrix and the low drug-loading capacity (Jenning et al.,
2000; Souto et al., 2006).
The Use of Carbohydrate-Based
Nanoparticles
Chitosan/Alginate Nanoparticles
Carbohydrates are naturally occurring organic substances that
serve both structural and storage functions (Ghazarian et al.,
2011). They are biodegradable, biocompatible substances, with
highly stable properties, and thus have attracted much attention
for their applications in the food, biomedical and environmental
fields (Chen and Soucie, 1985; Jizomoto et al., 1993; Richardson
et al., 1999; Melamu and Von Blottnitz, 2009). Chitosan, a
natural biopolymer produced by the deacetylation of chitin, is
one of the most commonly used polysaccharides for fabrication
of nanoparticles (Nitta and Numata, 2013). In addition to
being non-toxic, biodegradable, and biocompatible, chitosan is
characterized by its antibacterial activity, together with its ability
to deliver drug molecules and biological compounds to their
target destination (Richardson et al., 1999; Jia et al., 2001).
For example, chitosan nanoparticles have demonstrated high
efficiency for the delivery of diverse compounds, such as insulin,
genes, vaccines, and other molecules (Vila et al., 2004; Lavertu
et al., 2006; Li et al., 2009; Zhang et al., 2010). The combination of
chitosan and alginate has been shown to improve the characters
of both polymeric components and to provide better delivery
than that obtained by using each biopolymer separately (Murata
et al., 1993; Sezer and Akbuga, 1999). Such combination has
been successfully used to encapsulate nisin, with 95% entrapment
efficiency (Zohri et al., 2010). The encapsulated nisin has been
found to be released in high concentrations within the first 4 h,
followed by a steadily sustained release for more than 5 h (Zohri
et al., 2010). Regarding its biological activity, the nisin-loaded
chitosan/alginate has exhibited a much higher level of AMA
(about 2-folds higher) than that of the free nisin, when tested
against S. aureus ATCC 19117 (Zohri et al., 2010). Also, the
minimum inhibitory concentration (MIC) of the nisin-loaded
nanoparticles has been shown to be four times less than that
of the free nisin (0.5 and 2mg/ml, respectively; Zohri et al.,
2010). Additionally, the nisin-loaded nanoparticles have shown
significant growth-suppressing effects on S. aureus in both raw
and pasteurized milk samples, which remained for at least 24
and 48 h, respectively, compared to 14 and 24 h in case of the
free nisin (Zohri et al., 2010). These promising results have been
emphasized in another study performed by Zohri et al. (2013).
In their study, the nisin-loaded chitosan-alginate nanoparticles
have shown a higher level of AMA against L. monocytogenes
and S. aureus compared with the free nisin (Zohri et al.,
2013). Furthermore, this nano-polymer hybrid did not affect the
physicochemical characters of the tested food material (Zohri
et al., 2013). Similar studies have demonstrated the efficiency of
chitosan-based delivery systems for bacteriocins (Bernela et al.,
2014; Chopra et al., 2014). Among the advantages provided by
using this type of nanodelivery systems are: the potent, long-
lasting AMA, the sustained-release characteristics of the system,
and the maintenance of original food quality (Bernela et al.,
2014; Chopra et al., 2014). Therefore, it can be concluded that
harnessing of these biocompatible nanoparticles in the food
industry is a promising strategy for delivery of natural food
preservatives in high efficiency with fewer undesirable effects.
Phytoglycogen Nanoparticles
Phytoglycogen is a polysaccharide material found in plants,
which is commonly used for preparing novel functional
nanoconstructs (Chen et al., 2015). In addition to chitosan that
has been discussed earlier, phytoglycogen and its derivatives
represent another class of carbohydrate-based nanoparticles that
have been successfully used as carriers for nisin (Bi et al., 2011a).
When the capabilities of different phytoglycogen derivatives have
been examined as carriers of nisin, all the derivatives have
demonstrated a long-lasting AMA against L. monocytogenes, but
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the longest activity has been associated with octenyl succinate and
β-amylolysis substitutions (Bi et al., 2011a). Both phytoglycogen
derivatives have retained the activity of nisin against common
food pathogenic bacteria for 21 days, in comparison with 7
days in case of the free nisin (Bi et al., 2011a). In a similar
study, phytoglycogen octenyl succinate has been effectively
used to form an oil-in-water emulsion for delivering nisin
against L. monocytogenes (Bi et al., 2011b). The antibacterial
activity of this nanoparticle-stabilized emulsion has been higher
than that of the free nisin during 50 days of storage (Bi
et al., 2011b). Overall, these results encourage researchers to
exploit nanomaterials as carriers for bacteriocins, which may be
especially beneficial to the food industry, to ensure the safety
of food both at the packaging stage and after opening the
package.
Conjugation with Nanosized Metals
Conjugation with Gold Nanoparticles
Metal nanoparticles as gold, silver, copper, zinc have shown
potent AMA against pathogenic bacteria (Yoon et al., 2007;
Kuo et al., 2009; Raghupathi et al., 2011). Generally, this
is due to the large surface area of these positively charged
nanoparticles, which facilitates their binding to the negatively
charged bacterial membrane (Seil and Webster, 2012). The
targeted bacteria are then killed by the oxidative stress
induced by the generated reactive oxygen species, together
with the toxicity of the accumulated free metal ions (Seil
and Webster, 2012). This proposed mechanism of action sets
metal nanoparticles as a promising approach to solve the
problem of antimicrobial resistance. Therefore, combinations
of bacteriocins and nanosized metals are expected to have a
synergistic effect on antibacterial properties (Thirumurugan
et al., 2013). In a recent study, conjugates containing gold
nanoparticles with either nisin or a bacteriocin produced
by L. plantarum ATM11 have both displayed significant
AMA compared with the free bacteriocins, especially against
M. luteus, B. cereus, E. coli, and S. aureus (Thirumurugan et al.,
2013). This demonstrates the efficiency of such combinations
in extending the shelf-life of food products by inhibiting
a number of common food-spoilage microorganisms. In a
similar study, incorporation of a bacteriocin produced by
L. acidophilus CH1 with gold nanoparticles has resulted
in a formulation with potent activity against intestinal
microsporidiosis in immunocompromised mice (Mossallam
et al., 2014). This bacteriocin-gold nanoconjugate has displayed
89.7% reduction in the number of infected intestinal cells
and 93.65% reduction in the number of fecal spores, in
comparison with 73.5 and 81.29%, respectively, for the
free bacteriocin (Mossallam et al., 2014). In addition, the
activity of incorporated bacteriocin has been sustained (with
94.26% efficiency) up to 1 week after the end of the treatment
(Mossallam et al., 2014). Furthermore, this nanoconjugated
bacteriocin has been shown to be safe and non-toxic, as
demonstrated through behavior examinations, biochemical
analysis, and histopathological screening tests (Mossallam et al.,
2014).
Conjugation with Silver Nanoparticles
Silver nanoparticles are used in several applications, ranging from
coating medical devices, wound dressing, coating textile fabrics,
to water treatment and filtration (Furno et al., 2004; Rujitanaroj
et al., 2008; Zhang et al., 2009; Dankovich and Gray, 2011).
This is attributed to the broad-spectrum antimicrobial activity
possessed by these nanoparticles against most clinically relevant
organisms, including drug-resistant pathogens (Lara et al., 2010;
Zinjarde, 2012). However, maximizing the antimicrobial efficacy
of silver nanoparticles could be achieved by conjugating them
to antimicrobial agents, such as bacteriocins. This approach has
been demonstrated in a study conducted by Sharma et al. (2012),
in which enterocin-capped silver nanoparticles (En-SNPs) have
exhibited excellent efficiency against a wide range of Gram-
positive and Gram-negative pathogenic bacteria. The highest
level of activity of this En-SNPs has been shown against three
of the most common food poisoning organisms, namely E. coli,
L. monocytogenes, and S. aureus (Sharma et al., 2012). The MIC
values of this En-SNPs have been shown to be 2- to 16-fold
lower than that of citrate-capped silver nanoparticles (C-SNPs)
(Sharma et al., 2012). Furthermore, different concentrations
of En-SNPs have shown virtually no hemolytic effects against
human RBCs (Sharma et al., 2012). Such results strongly
motivate researchers to investigate the antibacterial activity
of other bacteriocins-silver nanoparticles conjugates. However,
more toxicological studies are needed to demonstrate the safety
of these conjugates (Oberdörster et al., 2005).
Incorporation into Polymeric Nanofibers
Nanofibers are extremely fine threads that are formed by spinning
a polymer solution using a high potential electric field (Anton,
1934). Given their large surface area, small pore size, high
physical stability, and powerful encapsulation ability (Doshi and
Reneker, 1993; Sharma et al., 2014), nanofibers have attracted
much attention as carriers for the target-specific delivery and
sustained release of a variety of drugs (Luong-Van et al., 2006;
Maretschek et al., 2008). In an application of this approach, an
antimicrobial nanofiber wound dressing has been generated by
electrospinning nisin into equimolar amounts of poly (ethylene
oxide) (PEO) and poly (D, L-lactide) (PDLLA) nanofibers
(Heunis et al., 2013). Nisin released from this nanofiber dressing
has been shown to: (i) maintain its antistreptococcal activity
in vitro for at least 4 days; (ii) remain active, even after storage
of the formulation at 4◦C for 8 months; (iii) significantly reduce
the colonization of S. aureus in a murine excisional skin infection
model; (iv) induce an almost complete wound repair, as indicated
by the formation of clear fibrotic scar in the group of mice
receiving the dressing; and (iv) cause no adverse effects, as
revealed by histological analysis of the treated group (Heunis
et al., 2013). Another similar study was carried out Heunis et al.
(2011), in which nanofibers prepared using different ratios of
PEO to PDLLA were used to incorporate plantaricin 423 and
bacteriocin ST4SA separately. The release studies showed that
a blend of PEO-PDLLA (90:10) resulted in a rapid release of
Plantaricin 423 within the first 2 h, followed by a slow and
constant release phase that extended for almost 8 days (Heunis
et al., 2011). This pattern of release is considered ideal for
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infection control, since the quickly released bacteriocins will
eliminate most of the microbial viable cells within the initial
hours of contact, while those slowly released over the following
few days are crucial for maintaining the infection under control
(Heunis et al., 2011). Similarly, plantaricin 423 and bacteriocin
ST4SA released from a blend of PEO-PDLLA (50:50) have been
shown to maintain their AMA against sensitive bacterial strains
for at least 6 days (Heunis et al., 2011).
Another example of polymeric nanofibers is the Poly-L-lactide
(PLA), which is a polymeric biodegradable material that can be
used as a drug delivery system once formulated in the nanoscale
(Ignatius and Claes, 1996; Perez et al., 2001; Liang et al., 2006).
In a study conducted by Salmaso et al. (2004), nisin has been
loaded with high capacity into PLA nanoparticles, which offered
a sustained-release formulation of the peptide (throughout
1000 h, depending on the pH and the salt concentration of
the buffer used). Regarding the biological activity, the nisin-
loaded PLA nanoparticles have displayed a potent AMA against
L. delbrueckeii lasting up to 45 days, while the activity of the free
nisin has been shown to last for 7 days only (Salmaso et al., 2004).
These results indicate the usefulness of PLA nanoparticles in
providing high stability and sustained release of the incorporated
bacteriocin, thereby increasing their applicability in the field
of food preservation. However, it must be mentioned that the
toxicity of PLA is still controversial (Athanasiou et al., 1996),
which requires further research on the biocompatibility of these
polymers with different cell types.
Recently, a novel strategy has been implemented to maximize
the benefits of bacteriocins in the biomedical field through the
exploitation of nanofibers as a delivery system. This strategy
depends on the electrospinning of potent bacteriocins and
other beneficial substances into nanofibers to target multidrug-
resistant bacteria and nosocomial pathogens. As an example
of this approach, a study conducted by Ahire et al. (Ahire
and Dicks, 2015) has investigated the activity of nisin after
being incorporated into nanofibers prepared from PDLLA and
PEO with another natural agent, called 2,3-dihydroxybenzoic
acid (DHBA). This combination has shown antibiofilm activity
against MRSA (Ahire and Dicks, 2015). Biofilm formation
decreased by 88% following 24 h of exposure to nanofibers
containing nisin and DHBA, compared to a 63% decrease
for nanofibers containing only DHBA, and a 3% decrease for
nanofibers containing nisin solely (Ahire and Dicks, 2015). The
ability of DHBA to chelate free iron, which is needed for biofilm
formation, is the proposed mechanism that explains the anti-
MRSA biofilm activity (Ahire and Dicks, 2015). In another
study, co-incorporation of nisin and silver nanoparticles into
nanofibers has resulted in a broad AMA against a wide range of
Gram-positive and resistant Gram-negative bacteria (Ahire et al.,
2015). These promising results may represent a new therapeutic
alternative to conventional wound dressing materials, especially
against antibiotic-resistant microorganisms.
CONCLUSION
Bacteriocins are a promising substitute for the currently
existing antibiotics that are becoming less effective in the
face of the increasing abundance of resistant organisms.
However, there are several limitations that challenge the use of
bacteriocins as biopreservatives / antibacterial agents in the food
and pharmaceutical industries. Nanodelivery systems, such as
lipid-, carbohydrate-, metal-, and polymer-based nanoparticles
represent promising approaches to maximize the use of these
antimicrobial peptides. Several examples of nanoformulated
bacteriocins have been shown to possess better stability and
a broader spectrum of antimicrobial activity in comparison
with the free ones. In conclusion, nanotechnological approaches
provide an interesting option toward the formulation of these
antimicrobial peptides at the industry-scale level.
FUTURE PERSPECTIVES
Bacteriocins have proven their efficiency as antibacterial agents,
which explains the currently available examples of these
peptides that have been commercially approved for application
in the food industry. On the other hand, exploitation of
bacteriocins in the health care and pharmaceutical industries
is moving forward less rapidly, which is a result of a
number of limitations and challenges that have yet to be
solved. One of the strategies to overcome these limitations
is to apply nanotechnological approaches to enhance the
applicability of bacteriocins, increase their stability, and extend
their antimicrobial spectrum of activity. While the different
approaches to produce these formulations include encapsulation
and nanomaterials conjugation, each of these approaches has
its own challenges, which need to be addressed to ensure
practicality of the approach. More studies are also needed to
clarify whether the use of other nanodelivery systems (such
as carbon nanotubes) or the combinations with nanoparticles
exhibiting AMA (such as zinc oxide) could enhance the
antimicrobial properties of bacteriocins. Additionally, the nature
of interactions between these peptides and nanomaterials,
as well as the interactions between nanoformulations of
these peptides and the targeted microorganisms need to
be elucidated. Further studies are also required to assess
the in vivo efficiency and the safety of these peptides.
A better understanding of these areas will pave the way
toward more clinical applications of bacteriocins in the near
future.
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